Nitroimidazoles such as misonidazole bind to hypoxic mammalian cells with an oxygen dependence similar to that for radioresistance. This has led to the use of misonidazole and related compounds as markers of hypoxic, radiation-resistant tumour cells. Numerous investigations have established the usefulness of the approach (Chapman, 1991) but nitroimidazoles also bind to some normoxic tissues and Cobb et al. (1990a,b) have questioned whether hypoxia marker binding is due to oxygen-dependent processes in all cases. A possible alternative is that local distributions of specific nitroreductase activity produce 2-nitroimidazole binding via oxygen-independent pathways. In support of this view, P450-dependent enzymes with expected nitroreductase activity (Belisario et al., 1990; Cenas et al., 1994) are known to be located in the pericentral region of liver tissue (review, Jungerman and Katz, 1989) where 2-nitroimidazoles bind Cobb et al., 1990a,b) . Furthermore, average oxygen concentrations of 20-120 IM in normal tissues (Jones, 1985; Thurman et al., 1986 ) might be expected to strongly inhibit 2-nitroimidazole binding given that the binding rate decreases sharply at oxygen concentrations above approximately 14 liM as measured by oxygen microelectrodes (Mueller-Klieser et al., 1991) . Nevertheless, there is experimental evidence that 2-nitroimidazole binding in many normal and tumour tissues is primarily dependent on oxygen concentration and not on the presence of specialised nitroreductases in the tissues. For example, MacManus et al. (1989) found that lowered tissue oxygen concentrations created by hypobaric oxygen inhalation increased the levels of misonidazole binding in mouse liver, kidney, spleen, heart and tumour tissues. Van Os-Corby et al. (1987) reported that neither the rates of binding nor the oxygen dependence of binding of misonidazole to isolated liver tissue was significantly different from that for brain, heart and tumour tissues. They also reported that binding rates in isolated hepatocytes were similar to or lower than those for other cells, and it was concluded that bioreductive enzymes in hepatocytes do not confer unique binding properties on these cells (Van Os-Corby, 1986 ). Parliament et al. (1992) found that inhibitors of the oxygen-independent nitroreductase, NAD(P)H:quinone (Thurman and Kauffman, 1985) in conjunction with the perfused liver model (e.g. Ballet and Thurman, 1991 ) lays a solid basis for answering the question in liver. As noted above, nitroimidazole binding in liver occurs near the central vein which is a region of low oxygen concentration and high cytochrome P450-dependent, redox enzyme activity (Jungerman and Katz, 1989 (Thurman and Kauffman, 1985) . For (Smithen and Hardy, 1982) and characterised by standard chromatographic, elemental analysis and spectrographic techniques. Radioactive pimonidazole labelled with tritium at the 2-position of the sidechain was prepared in our laboratories by an adaptation of the technique used to label misonidazole (Born and Smith, 1983 (Figures 1 and 2 ) and a mouse monoclonal antibody was used for the immunohistochemical studies (Figures 3 and 4) . Polyclonal antisera were used for the ELISA because they had been calibrated previously. Monoclonal antibodies were used for immunohistochemistry because they were more compatible with the batchprocessing, capillary-action, immunostaining technique used for the slide-mounted tissue sections (Microprobe, Fisher Scientific). Competitive ELISA indicated that monoclonal and polyclonal antibodies recognised the same antigen; i.e. the sidechain of pimonidazole.
For the preparation of the immunogens for both polyclonal and monoclonal antibody production, pimonidazole was bound to lipid-free, thiolated BSA by means of a radiation chemical reduction described previously (Raleigh and Koch, 1990) . BSA adducts of tritium-labelled pimonidazole of known specific activity were prepared in a similar manner and used to calibrate the ELISA. The solid phase antigen for the ELISA was prepared by radiation chemical reduction of pimonidazole in the presence of thiolated Ficoll. Thiolated Ficoll was produced by an adaptation of published procedures (Inman, 1975) with N-succinimidyl 3-(2-pyridyldithio)propionate (Pierce) serving as the source of latent thiol groups.
The rabbit polyclonal, anti-pimonidazole antisera used in the calibrated ELISA were prepared and characterised in a manner analogous to that for CCI-103F -a 2-nitroimidazole compound with six fluorine atoms on the sidechain (Raleigh et at., Cline et al., 1990 Immunohistochemical patterns ofpimonidazole binding in liver As expected, immunostaining in livers perfused at low flow rates in the anterograde direction was localised in oxygenpoor, centrilobular regions ( Figure 3a ). The pattern of immunostaining was reversed in liver perfused in the retrograde direction; that is, the staining was now localised in the oxygen-poor, periportal region of the tissue (Figure 3b ). The only exception to this reversal of immunostaining when the oxygen gradient was reversed was the immunostaining of the single layer of cells directly adjacent to the pericentral vein following retrograde perfusion (Figure 3c ). No such layer of immunostained cells was observed next to the periportal area following perfusion in the anterograde direction.
At high magnification (x 1000, Figure 3d ), immunostaining increased from background levels to dense staining over 1-2 cell diameters. In lightly stained cells, the staining was distributed equally over the nucleus and cytoplasm. In more heavily stained cells, an intensified immunostaining was observed over cell nuclei.
Image analysis of immunostained liver sections Quantitative image analysis (Figure 4 ) revealed that the fraction of liver tissue immunostained in the periportal regions during perfusion in the retrograde direction was not significantly different from that observed for the pericentral regions during perfusion in the anterograde direction. The single layer of immunostained cells around the central vein did not contribute significantly to the fraction of tissue area labelled during perfusion in the retrograde direction.
Discussion
The microregional patterns of 2-nitroimidazole binding (Figure 3 ) are completely consistent with the distribution of oxygen in liver perfused at low flow rates. There is no evidence that specialised nitroreductase activity located in the pericentral region of liver dominates the binding process as Cobb et al. (1990a,b) suggested. The results presented here indicate that oxygen-dependent nitroreductase activity is homogenously distributed in liver so that 2-nitroimidazole binding will occur whenever regional oxygen concentrations decline to such a level that electrons flow to the nitroaromatic compounds rather than to oxygen. This conclusion is in agreement with the known distribution of reducing equivalents and nitroreductases in liver.
With respect to the distribution of reducing equivalents, previous studies have shown that the potential for oxygen uptake is similar in periportal and pericentral regions of liver (Matsumura et al., 1986) . That is, the high rate of oxygen uptake in periportal regions during perfusion in the normal or anterograde direction is shifted to the pericentral region during perfusion in the retrograde direction. Importantly, about 85% of oxygen consumption in liver tissue is due to oxygen reduction by electrons from the electron transport chain (Matsumura et al., 1986) . These are the same electrons that reduce nitroaromatic compounds in the absence of oxygen so it is not surprising that the potential for nitroimidazole reduction and binding (Figure 3) , like oxygen uptake, is similar in pericentral and periportal regions of liver.
With respect to the distribution of nitroreductases, it is true that cytochrome P450-dependent nitroreductases are localised predominantly in pericentral regions (Jungerman and Katz, 1989) , but other nitroreductases such as aldehyde dehydrogenase (Wolpert et al., 1973) are distributed throughout liver tissue (Kashiwagi et al., 1983) . Enzyme distributions are not altered during liver perfusion experiments (Thurman and Kauffman, 1985) and it is unlikely that measurable enzyme induction would occur during 50 min of low-flow perfusion. Incubation under hypoxia for prolonged periods (> 8 h) is generally required to induce redox enzymes such as DT-diaphorase (e.g. Phillips et al., 1994) and subsequent, prolonged incubation under aerobic conditions is often needed for the changes induced under hypoxia to be detectable (e.g. O'Dwyer et al., 1994 ). This appears to be the case for liver tissue in vivo as well. For example, 8-9 days of chronic in vivo hypoxia induced by inhalation of 10% oxygen produced no detectable changes in rat hepatic cytochrome P450 content (Aw et al., 1991) .
If regional cytochrome P450-dependent nitroreductase activity accounted for hypoxia marker binding in liver tissue perfused in the anterograde direction, then perfusion in the retrograde direction should leave the binding pattern unchanged. That is, pimonidazole bioreduction would be analogous to mono-oxygenation in phenobarbital-treated rats which follows the distribution of cytochrome P450s irrespective of the direction of perfusion (Thurman and Kauffman, 1985) . However, the pattern of pimonidazole binding follows the distribution of oxygen in the tissue being completely reversed after perfusion in the retrograde direction (Figure 3a and b). Bioreductive activation of pimonidazole appears to Binding of 2-nitroimidazoles to normal etssue GE Arteel et al 894 fall, therefore, into the class of processes such as oxygen uptake for which underlying metabolic systems are available uniformly throughout the liver. In support of this conclusion, the extent of binding around the portal triad during retrograde perfusion is quantitatively similar to that around the central vein during anterograde perfusion (Figure 4) Pimonidazole binding in the rim of cells around the central vein during perfusion in the retrograde direction is a minor but interesting exception (Figure 3c ). The single layer of cells around the central vein is unique in other ways. For example, these cells are the only cells in liver that possess the enzyme glutamine synthetase (Gebhardt et al., 1988) . This enzyme is involved in ammonia detoxification and pH homeostasis (Haussinger et al., 1986 ) but it would not appear to be capable of reductively activating 2-nitroimidazole compounds. It is possible that these cells possess unique nitroreductase activity in addition to specialised ammonia metabolism although further work will be needed to confirm this. In any case, the possibility that these cells or the microregional distribution of specialised nitroreductase activity accounts for the predominant pattern of hypoxia marker binding in liver is not supported by the present experiments.
It is known that intracellular uptake of weak bases such as pimonidazole (pK, 8.6 at 37°C) can be influenced by changes in extracellular pH. While normoxic liver has mechanisms for pH homeostasis (Haussinger et al., 1986) , acidosis can accompany hypoxia/ischaemia in other tissues and it is appropriate to consider the effect that changes in pH might have on pimonidazole binding. For an extracellular pH of 7.3, pimonidazole concentration exceeds that in the surrounding medium by a factor of 2-3 for both rodent and human tumour cells (Dennis et al., 1985; Watts et al., 1990) but as the extracellular pH declines to 6.6, intracellular pimonidazole concentration falls to match that in the surrounding medium (Dennis et al., 1985) . This decrease in intracellular concentration is accompanied by a parallel decrease in the intensity of pimonidazole binding to cellular glutathione and macromolecules. For example, a change in extracellular pH from 7.3 to 6.8 leads to a decrease in the concentration of glutathione and macromolecular adducts by a factor of 2-3 (JM Yates et al., 1995, unpublished) . A decrease in extracellular pH in hypoxic regions could, therefore, decrease pimonidazole binding. However, this effect is small compared with the 12-fold difference in binding intensity between anoxic and aerated cells (Figure 2 ) and, with respect to the present experiments, in the wrong direction since binding was observed to increase, not decrease, in the hypoxic regions of perfused liver. In the image analysis of hypoxia marker binding (Figure 4 ) it should be noted that, once the threshold intensity distinguishing stained from unstained cells is established, small differences in the intensity of pimonidazole binding among cells in the immunostained regions are not registered. The ELISA data do reflect intensity differences but, in fact, they revealed no significant difference in binding intensity between pericentral and periportal regions. Therefore, we conclude that changes in pH did not play a role in pimonidazole binding patterns observed in the perfused liver experiments. Hypoxia markers do not provide a precise measure of oxygen concentration in tissues but it is reasonable to assume, based on comparison with misonidazole, that halfmaximal inhibition of pimonidazole binding in vivo occurs in the range of 1-6 tM oxygen (Franko and Koch, 1984) .
While this concentration range is well below the values measured in normal tissues with oxygen electrodes, the present results show that oxygen gradients are created on a cellular scale (Figure 3d ) so that average tissue P02 is not a good predictor of 2-nitroimidazole binding under normoxic conditions. Hypoxia markers were developed primarily for use in tumours where the patterns of binding have been found to be consistent with the distributions of oxygen expected on the basis of the Thomlinson and Gray (1955) analysis of carcinomas of the human bronchus. Nevertheless, the hypoxia marker technique is dependent on nitroreductase activity in tissues and there is little control of this aspect of the assayparticularly in a clinical setting. The challenge posed by the observation that 2-nitroimidazoles bind to some normoxic tissues cannot, therefore, be ignored. It raises the mechanistic question of whether binding in all cases is due to low oxygen concentration and the practical question of whether normal tissue hypoxia will interfere with the use of hypoxia markers in tumours. From a mechanistic point of view, the demonstration that the binding of 2-nitroimidazoles in liver tissue is primarily dependent on oxygen concentration provides support for the idea that hypoxia markers, in general, reflect patterns of oxygen concentrations in normal and tumour tissue. From a practical point of view, this opens up the possibility that hypoxia markers will be useful in studies of liver pathophysiology associated with changes in liver oxygenation as appears to be the case for alcohol-induced liver damage Arteel et al., 1995) . Hypoxia markers might also be used in identifying normal tissues at risk with respect to hypoxia-dependent cytotoxins or to radiation sensitisation by procedures designed to increase tissue P02* Carbogen breathing, for example, increases radiation sensitivity in skin (Rojas et al., 1992) as hypoxia marker binding would predict. Finally, the results of the present study support the premise underlying the development of the immunohistochemical, hypoxia marker method.
Non-invasive hypoxia marker techniques might be useful in following changes in tumour hypoxia, but a biopsy-based, histological investigation of tumour hypoxia is the only way to discriminate between hypoxia in tumour and surrounding normal tissue (Raleigh et al., 1987) .
